Table 3.
Microstructural properties of the fifth lumbar (L5) vertebral body
| Placebo + Control (n = 10) | Placebo + AAV8-Ostn (n = 7) | Prednisolone + Control (n = 7) | Prednisolone + AAV8-Ostn (n = 6) | |
|---|---|---|---|---|
| BV/TV (%) | 27.71 ± 2.73 | 29.71 ± 3.61 | 26.79 ± 2.47a | 26.16 ± 2.80a |
| BMD (mgHA/cm3) | 275 ± 27 | 293 ± 31 | 266 ± 26a | 260 ± 21a |
| Tb. N. (1/mm) | 4.72 ± 0.31 | 4.73 ± 0.21 | 4.55 ± 0.22 | 4.74 ± 0.24 |
| Tb. Th. (mm) | 0.058 ± 0.003 | 0.061 ± 0.004 | 0.058 ± 0.005 | 0.056 ± 0.003 |
| Tb. Sp. (mm) | 0.211 ± 0.016 | 0.212 ± 0.011 | 0.220 ± 0.012 | 0.209 ± 0.010 |
| ConnD. (1/mm3) | 194 ± 21 | 180 ± 18 | 193 ± 33 | 201 ± 22 |
| SMI | 0.317 ± 0.211 | 0.152 ± 0.343 | 0.447 ± 0.253a | 0.542 ± 0.276a,b |
Properties measured in the L5 vertebra include bone volume fraction (BV/TV), bone mineral density (BMD), trabecular number (Tb. N.), trabecular thickness (Tb. Th.), trabecular separation (Tb. Sp.), connectivity density (ConnD.) and structural model index (SMI). All values are presented as mean ± SD
a
Overall effect of prednisolone p < 0.05, two-way ANOVA.
b
p < 0.05 compared to the corresponding placebo group by Sidak’s multiple comparisons tests.